statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024...

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting Coeptis Therapeutics Announces Poster Data Presentation at American...

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award Coeptis Therapeutics Congratulates...

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK Coeptis Therapeutics Adds Autoimmune Indications to...

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections Coeptis Therapeutics to Pursue Phase 2 Program Using...

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 Coeptis Therapeutics President and CEO Issues Letter to Shareholders...

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Watchers	2,203
52-Wk Low	$0.2851
52-Wk High	$2.19

Volume	43,403.00
52-Wk High	$2.19
52-Wk Low	$0.2851

COEP Coeptis Therapeutics Holdings Inc

About

Feed

News

Sentiment

Fundamentals

Sentiment

Message Volume

Community